Synovial sarcoma is a rare cancer that develops in soft tissues like muscle, fat, and fibrous tissue. It accounts for roughly 5% to 10% of all soft tissue sarcomas, and it typically strikes younger adults, with a median age at diagnosis of about 30 years. Despite its name, it does not come from the synovial lining of joints. The word “synovial” is a historical misnomer that stuck because early pathologists thought the tumor cells resembled joint tissue under a microscope.
Where It Develops and What It Feels Like
Synovial sarcoma most commonly shows up in the arms, legs, or feet, particularly near joints like the wrist or ankle. It can also form in less typical locations, including the soft tissues of the lungs or abdomen. The tumor can technically appear anywhere in the body.
The first sign is usually a painless lump that grows slowly over weeks or months. Because it doesn’t hurt at first, many people assume it’s a benign cyst or muscle strain and delay getting it checked. If the tumor sits near a nerve, it may eventually cause pain, tingling, or numbness as it enlarges. Tumors in the chest or abdomen may not produce obvious symptoms until they’re large enough to press on surrounding organs.
What Causes It
Synovial sarcoma is driven by a specific genetic error: a translocation where portions of two chromosomes swap material. This swap creates an abnormal fusion protein that disrupts normal cell regulation and drives tumor growth. The translocation is found in virtually all synovial sarcoma cases and serves as a reliable identifier when doctors are trying to confirm the diagnosis. This genetic change is not inherited from parents. It occurs spontaneously in a single cell during a person’s lifetime, and no clear environmental risk factors have been established.
How It’s Diagnosed
After imaging (usually an MRI to assess the tumor’s size and location), a biopsy is needed for a definitive diagnosis. Under a microscope, pathologists classify synovial sarcoma into two main subtypes:
- Monophasic: Made entirely of uniform, spindle-shaped cells packed in dense sheets. This is the more common form and can be harder to distinguish from other soft tissue tumors based on appearance alone.
- Biphasic: Contains two intermingled cell populations. One resembles the spindle cells seen in monophasic tumors, while the other shows features of epithelial cells, the type that line surfaces like skin and organ cavities.
Because synovial sarcoma can look similar to other soft tissue cancers, confirming the characteristic chromosomal translocation through molecular testing is a critical step. Labs use techniques like fluorescence in situ hybridization (FISH) or PCR to detect the fusion gene and lock in the diagnosis.
Treatment for Localized Tumors
Surgery is the primary treatment. The goal is a wide excision, removing the tumor along with a margin of healthy tissue around it, to minimize the chance of recurrence. Surgeons aim to preserve limb function whenever possible, and advances in reconstructive surgery have made amputation rare except in the most extreme cases. Simply “shelling out” the visible tumor without clean margins significantly raises the risk of the cancer returning locally.
Radiation therapy is commonly added before or after surgery, especially for larger or higher-grade tumors. It reduces local recurrence but has not been shown to improve overall survival in clinical trials. Pre-surgical radiation typically uses smaller treatment fields and lower doses than post-surgical radiation, which can mean fewer side effects to surrounding tissue. The choice between the two depends on the tumor’s size, location, and the surgical plan.
Synovial sarcoma is classified as a high-grade cancer. For small tumors (5 cm or less) with clean surgical margins, long-term local control rates reach about 90% with surgery alone. However, because synovial sarcoma is known for late recurrences, sometimes appearing more than five years after the original diagnosis, long-term follow-up with periodic imaging is standard.
Chemotherapy for Advanced Disease
One relatively encouraging feature of synovial sarcoma is that it responds better to chemotherapy than many other soft tissue sarcomas. In a large European review of clinical trials, synovial sarcoma patients had a response rate of about 28%, compared to 19% for soft tissue sarcomas overall. Median overall survival was also longer: 15 months versus nearly 12 months.
The preferred first-line combination for patients with metastatic or unresectable disease pairs two chemotherapy agents, with response rates around 32%. For patients who aren’t candidates for aggressive combination therapy, sequential single-agent treatment is an alternative. If the cancer progresses after first-line treatment, a targeted oral medication called pazopanib is one option. In clinical trials, 6% of patients on pazopanib had measurable tumor shrinkage, and another 67% had their disease stabilized, translating to a median progression-free survival of about 4.6 months compared to 1.6 months with placebo.
Engineered T-Cell Therapy
In August 2024, the FDA granted accelerated approval to a new type of treatment specifically for synovial sarcoma: a T-cell therapy called afamitresgene autoleucel. This is one of the first cell-based immunotherapies approved for a solid tumor (most previous approvals were for blood cancers).
The treatment works by collecting a patient’s own immune cells, genetically reprogramming them in a lab to recognize a specific protein found on the surface of synovial sarcoma cells, and then infusing those modified cells back into the patient. In the clinical trial that led to approval, 44 patients with advanced synovial sarcoma who had already tried chemotherapy received a single infusion. The overall response rate was 43%, with tumors beginning to shrink in a median of about 5 weeks. Among those who responded, roughly 39% maintained their response for a year or longer.
Not every patient is eligible. The therapy requires a specific immune tissue type (carried by a subset of the population) and the tumor must express the protein the engineered cells are designed to target. Both are confirmed through companion diagnostic tests before treatment. The most significant risk is cytokine release syndrome, an intense inflammatory reaction that can be severe or life-threatening and requires close monitoring in a specialized center.
Survival Rates and Outlook
Prognosis depends heavily on how far the cancer has spread at diagnosis. Five-year relative survival rates for soft tissue sarcomas, based on data from 2015 to 2021, break down by stage:
- Localized (confined to the original site): 83%
- Regional (spread to nearby structures or lymph nodes): 60%
- Distant (spread to organs like the lungs): 17%
These figures cover all soft tissue sarcomas grouped together, so individual outcomes for synovial sarcoma vary depending on tumor size, location, grade, and response to treatment. Lymph node involvement is uncommon in most sarcomas but occurs more frequently with synovial sarcoma than with many other subtypes. The tendency for late recurrence also means that even patients who are disease-free at five years continue to need surveillance.
Tumor size at diagnosis is one of the strongest predictors of outcome. Smaller tumors that are caught before they spread offer the best chance of long-term control, which is why any persistent, unexplained lump in the soft tissues, especially near a joint, is worth getting evaluated promptly.